Comparative Pharmacology
Head-to-head clinical analysis: QUINACT versus QUINIDINE GLUCONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINACT versus QUINIDINE GLUCONATE.
QUINACT vs QUINIDINE GLUCONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
Class Ia antiarrhythmic agent; blocks sodium channels (Nav1.5) and potassium channels (IKr, IKs), prolongs action potential duration and effective refractory period; also has anticholinergic and alpha-adrenergic blocking effects.
100 mg orally three times daily.
324-648 mg orally every 8-12 hours; maximum 3.24 g/day. Also administered IV as quinidine gluconate 200-400 mg (diluted) at a rate ≤1 mL/min.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Terminal elimination half-life: 6-8 hours (range 4-12 hours) in healthy adults; prolonged in HF, renal impairment, or elderly.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: 50-70% unchanged; Biliary/fecal: 20-30%; Hepatic metabolism accounts for 10-30%.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)